Expanded Access Program

Emalex has completed its Phase 3 program for Tourette syndrome and has progressed to the Expanded Access Program (EAP).

This study (EBS-101-TD-392) “An Open Labeled Expanded Access Program Intended to Provide Treatment with Ecopipam (EBS-101) to Children, Adolescents and Adults in the US with Tourette’s Disorder,” is currently enrolling.

You can contact Emalex Biosciences at medicalaffairs@emalex.com for further information about this study or click here